- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02642263
Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain
May 3, 2018 updated by: University Hospital Inselspital, Berne
Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain, A Prospective Randomised Study
Carbetocin is an oxytocin agonist used for prevention of postpartum bleeding after cesarean delivery.
First studies revealed in 2012 an analgesic effect of carbetocin, compared to its parent substance oxytocin.
This study will enroll 78 women undergoing cesarean delivery.
In a double-blind, prospective design patients will be either attributed to the oxytocin or the carbetocin study arm.
The primary endpoint will be the area of hyperalgesia around the cesarean delivery scar.
This will be performed with a von Frey hair, resulting in a unpleasant feeling in the area of hyperalgesia.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
78
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bern, Switzerland, 3010
- Dep. of Anesthesiology and Pain Medicine, Bern University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age 18-45, uneventful pregnancy, on term (>37 0/7 weeks of gestation), scheduled elective CS including repeat CS
Exclusion Criteria:
- lack of informed consent, active labor, multiple pregnancy, polyhydramnios, severe fetal malformations
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Oxytocin
Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby.
For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
|
|
|
Experimental: Carbetocin
100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby.
For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
|
Postpartum uterotonic drug
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cesarean delivery scar cutaneous hyperalgesia
Time Frame: 4 hours after cesarean delivery
|
In the area of the cesarean delivery scar, the area of dynamic secondary hyperalgesia for punctate mechanical stimuli around the surgical incision will be measured around her scar according to the method described by Stubhaug et al.
In brief, stimulation with a Von Frey Filament (225.1gr) is started from outside the hyperalgesic area where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception.
The first point where a painful, sore, or sharp feeling appears is recorded, and the distance to the incision is measured.
If no change in sensation appears, stimulation is stopped at 0.5 cm from the incision.
The area of secondary hyperalgesia is determined by testing along radial lines separated by 5 cm around the incision.
The observations are translated onto graph paper, and the surface is calculated as cm2/cm of incision.
|
4 hours after cesarean delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pressure pain detection threshold
Time Frame: before cesarean
|
Pain detection thresholds will be measured with an electronic pressure algometer (Algometer, Somedic, Denmark) applied at the center of the pulp of the 2nd toe.
The probe has a surface area of 1 cm2.
The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa.
Pain detection threshold is defined as the point at which the pressure sensation turns to pain.
The subjects are instructed to press a button when these points are reached.
The algometer displays the pressure intensity at which the button is pressed.
If the subjects do not press the button at a pressure of 1000 kPa, this value is considered as threshold.
|
before cesarean
|
|
Pressure pain detection threshold
Time Frame: 4 hours after cesarean
|
Pain detection thresholds will be measured with an electronic pressure algometer (Algometer, Somedic, Denmark) applied at the center of the pulp of the 2nd toe.
The probe has a surface area of 1 cm2.
The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa.
Pain detection threshold is defined as the point at which the pressure sensation turns to pain.
The subjects are instructed to press a button when these points are reached.
The algometer displays the pressure intensity at which the button is pressed.
If the subjects do not press the button at a pressure of 1000 kPa, this value is considered as threshold.
|
4 hours after cesarean
|
|
Pressure pain detection threshold
Time Frame: 24 hours after cesarean
|
Pain detection thresholds will be measured with an electronic pressure algometer (Algometer, Somedic, Denmark) applied at the center of the pulp of the 2nd toe.
The probe has a surface area of 1 cm2.
The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa.
Pain detection threshold is defined as the point at which the pressure sensation turns to pain.
The subjects are instructed to press a button when these points are reached.
The algometer displays the pressure intensity at which the button is pressed.
If the subjects do not press the button at a pressure of 1000 kPa, this value is considered as threshold.
|
24 hours after cesarean
|
|
Pressure pain detection threshold
Time Frame: 48 hours after cesarean
|
Pain detection thresholds will be measured with an electronic pressure algometer (Algometer, Somedic, Denmark) applied at the center of the pulp of the 2nd toe.
The probe has a surface area of 1 cm2.
The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa.
Pain detection threshold is defined as the point at which the pressure sensation turns to pain.
The subjects are instructed to press a button when these points are reached.
The algometer displays the pressure intensity at which the button is pressed.
If the subjects do not press the button at a pressure of 1000 kPa, this value is considered as threshold.
|
48 hours after cesarean
|
|
Pressure pain detection threshold
Time Frame: 6 weeks after cesarean
|
Pain detection thresholds will be measured with an electronic pressure algometer (Algometer, Somedic, Denmark) applied at the center of the pulp of the 2nd toe.
The probe has a surface area of 1 cm2.
The pressure is increased from 0 at a rate of 30kPa/s to a maximum pressure of 1000kPa.
Pain detection threshold is defined as the point at which the pressure sensation turns to pain.
The subjects are instructed to press a button when these points are reached.
The algometer displays the pressure intensity at which the button is pressed.
If the subjects do not press the button at a pressure of 1000 kPa, this value is considered as threshold.
|
6 weeks after cesarean
|
|
Baseline depression detection
Time Frame: before cesarean
|
Beck Depression Inventory (BDI-II): a 21 question multiple choice inventory used to measure severity of depression.
This will be used in order to assess an eventual prepartum depression, this measure aims at eliminating bias if detecting a postpartum depression by the Edinburgh Depression questionnaire
|
before cesarean
|
|
Postpartum depression
Time Frame: 6 weeks post cesarean
|
Assessment of postpartum depression with the Edinburgh Postnatal Depression Scale.
It is a 10 item questionnaire.
|
6 weeks post cesarean
|
|
Cesarean delivery scar cutaneous hyperalgesia
Time Frame: 24 hours after cesarean
|
In the area of the cesarean delivery scar, the area of dynamic secondary hyperalgesia for punctate mechanical stimuli around the surgical incision will be measured around her scar according to the method described by Stubhaug et al.
In brief, stimulation with a Von Frey Filament (225.1gr) is started from outside the hyperalgesic area where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception.
The first point where a painful, sore, or sharp feeling appears is recorded, and the distance to the incision is measured.
If no change in sensation appears, stimulation is stopped at 0.5 cm from the incision.
The area of secondary hyperalgesia is determined by testing along radial lines separated by 5 cm around the incision.
The observations are translated onto graph paper, and the surface is calculated as cm2/cm of incision.
|
24 hours after cesarean
|
|
Cesarean delivery scar cutaneous hyperalgesia
Time Frame: 48 hours after cesarean
|
In the area of the cesarean delivery scar, the area of dynamic secondary hyperalgesia for punctate mechanical stimuli around the surgical incision will be measured around her scar according to the method described by Stubhaug et al.
In brief, stimulation with a Von Frey Filament (225.1gr) is started from outside the hyperalgesic area where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception.
The first point where a painful, sore, or sharp feeling appears is recorded, and the distance to the incision is measured.
If no change in sensation appears, stimulation is stopped at 0.5 cm from the incision.
The area of secondary hyperalgesia is determined by testing along radial lines separated by 5 cm around the incision.
The observations are translated onto graph paper, and the surface is calculated as cm2/cm of incision.
|
48 hours after cesarean
|
|
Cesarean delivery scar cutaneous hyperalgesia
Time Frame: 6 weeks after cesarean
|
In the area of the cesarean delivery scar, the area of dynamic secondary hyperalgesia for punctate mechanical stimuli around the surgical incision will be measured around her scar according to the method described by Stubhaug et al.
In brief, stimulation with a Von Frey Filament (225.1gr) is started from outside the hyperalgesic area where no pain sensation is experienced toward the incision until the patient reports a distinct change in perception.
The first point where a painful, sore, or sharp feeling appears is recorded, and the distance to the incision is measured.
If no change in sensation appears, stimulation is stopped at 0.5 cm from the incision.
The area of secondary hyperalgesia is determined by testing along radial lines separated by 5 cm around the incision.
The observations are translated onto graph paper, and the surface is calculated as cm2/cm of incision.
|
6 weeks after cesarean
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Daniel Surbek, Prof, Bern University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2019
Primary Completion (Anticipated)
December 1, 2020
Study Completion (Anticipated)
January 1, 2022
Study Registration Dates
First Submitted
December 21, 2015
First Submitted That Met QC Criteria
December 23, 2015
First Posted (Estimate)
December 30, 2015
Study Record Updates
Last Update Posted (Actual)
May 4, 2018
Last Update Submitted That Met QC Criteria
May 3, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Uterotonic Carbetocin
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Delivery
-
Charite University, Berlin, GermanyCompletedCesarean Section Complications | Cesarean Delivery Affecting Newborn | Cesarean Delivery Affecting FetusGermany
-
Columbia UniversityNot yet recruitingDexmedetomidine | Postoperative Analgesia | Cesarean Delivery | Cesarean Delivery; Neuraxial Opioids | Clonidine | Spinal Anesthesia for Cesarean SectionUnited States
-
Insel Gruppe AG, University Hospital BernRecruitingCesarean Section | Delivery, Obstetric | Obstetric DeliverySwitzerland
-
Rambam Health Care CampusRecruitingCesarean Delivery Affecting Fetus | Delivery ComplicationIsrael
-
Assiut UniversityMinistry of Health, KuwaitNot yet recruiting
-
University of CalgaryCompleted
-
Assiut UniversityUnknown
-
Mansoura UniversityRecruitingCesarean Delivery | Spinal Anesthesia for Cesarean SectionEgypt
-
Ege UniversityNot yet recruitingCesarean DeliveryTurkey (Türkiye)
-
Women's Hospital School Of Medicine Zhejiang UniversityRecruiting
Clinical Trials on Carbetocin
-
Ciusss de L'Est de l'Île de MontréalCompletedCesarean Section Complications | Hemodynamic InstabilityCanada
-
University Hospital, Basel, SwitzerlandObstetric Anaesthetists' Association United KingdomCompletedAnesthesia; Reaction | Complications; Cesarean SectionSwitzerland
-
Levo Therapeutics, Inc.CompletedPrader-Willi SyndromeUnited States, Canada, Australia
-
ACADIA Pharmaceuticals Inc.Enrolling by invitationHyperphagia in Prader-Willi SyndromeUnited States, Canada, Spain, Germany, United Kingdom, France
-
Samuel Lunenfeld Research Institute, Mount Sinai...RecruitingPostpartum Hemorrhage (Primary)Canada
-
Mehmet Mete KırlangıçCompletedPostpartum Hemorrhage | CarbetocinTurkey (Türkiye)
-
University of British ColumbiaEdwards LifesciencesCompletedPregnancy | Effect of Carbetocin on Cardiovascular SystemCanada
-
Bezmialem Vakif UniversityCompleted
-
Cairo UniversityCompletedAbdominal MyomectomyEgypt
-
ACADIA Pharmaceuticals Inc.Active, not recruitingHyperphagia in Prader-Willi SyndromeUnited States, Spain, Canada, Germany, United Kingdom, France